-
摘要:
目的 本研究旨在确定念珠菌血症的危险因素, 评估肿瘤患者中近平滑假丝酵母菌和其他念珠菌之间可能存在的临床显著性差异。并对白假丝酵母菌血症和近平滑假丝酵母菌血症的临床特点及危险因素进行统计学分析, 旨在通过该类分析, 及时开展干预, 尽量避免易感因素, 进而改善真菌血症患者预后。 方法 回顾性分析郑州大学附属肿瘤医院2012年3月至2018年2月323例念珠菌血症患者的资料。分析患者发生念珠菌血症的危险因素, 同时对比分析近平滑假丝酵母菌和非近平滑假丝酵母菌、白假丝酵母菌和非白假丝酵母菌念珠菌血症的临床差异。通过微量肉汤稀释法对念珠菌常见抗真菌药物进行药敏试验和分析。 结果 念珠菌血症分离病原体中, 最常见的为近平滑假丝酵母菌37.15%(120/323), 而白假丝酵母菌占34.37%。多变量回归分析结果表明, 下述因素与近平滑假丝酵母菌念珠菌血症的发生相关, 即肠外营养(P < 0.001)、粒缺(P < 0.001)、化疗(P < 0.001)和抗真菌药物的使用(P < 0.001), 同时肠外营养为近平滑假丝酵母菌念珠菌血症发生的独立危险因素(OR=0.183, 95%CI:0.098~ 0.340;P < 0.001)。 结论 近平滑假丝酵母菌超越白假丝酵母菌为患者念珠菌血症主要病原体。通过评估患者念珠菌血症发生的可能危险因素, 以期加强和制定感染控制策略, 从而预防念珠菌血症的传播。 Abstract:Objects To clarify the risk factors of candidemia and to assess the clinical differences that may exist between infection with Candida parapsilosis and that with other Candida species in cancer patients. To statistically analyze the clinical characteristics of Candida albicans candidemia and C. parapsilosis candidemia and risk factors for their infections. We aimed at a timely intervention through this type of analysis to avoid susceptible factors and improve the prognosis of patients with candidemia. Methods We retrospectively included 323 patients with candidemia in Affiliated Cancer Hospital of Zhengzhou University between March 2012 and February 2018 and analyzed the clinical characteristics of these patients to establish the risk factors of candidemia. We performed a comparative analysis of the clinical characteristics of C. parapsilosis infections and non-parapsilosis Candida spp. infections and of C. albicans infections and non-albicans Candida spp. infections. In addition, drug sensitivity tests and analyses were performed with the common antifungal drugs used in Candida infections by a micro-broth dilution method. The statistical software SPSS version 22 was used for the analyses. Results A total of 323 patients were enrolled and analyzed in this study. Of the isolates, 34.37% were C. albicans and 65.63% were non-albicans Candida spp. Multivariate regression analysis showed that the following factors were associated with the occurrence of C. parapsilosis candidemia: parenteral nutrition (P < 0.001), neutropenia (P < 0.001), history of receiving chemotherapy (P=0.002), and history of previous antifungal use (P < 0.001). Parenteral nutrition was found to be an independent risk factor for C. albicans candidemia (OR=0.183; 95%CI:0.098-0.340; P < 0.001). Conclusions C. parapsilosis was found to be the primary pathogen in cancer patients with candidemia. Total parenteral nutrition in the intensive care unit at diagnosis and abdominal surgery were independent risk factors of candidemia, and parenteral nutrition was an independent risk factor of C. parapsilosis candidemia. At present, C. parapsilosis is surpassing C. albicans as the main pathogen of candidemia in cancer patients at our hospital. This study emphasizes the need to assess the possible risk factors for candidemia in cancer patients and aims at strengthening and developing a hospital-based control strategy to prevent the spread of candidemia. -
Key words:
- candidemia /
- malignancy /
- C.albicans /
- C.parapsilosis
-
表 1 323例肿瘤患者真菌血症特征
表 2 非近平滑假丝酵母菌血症和近平滑假丝酵母菌血症相关因素分析
表 3 常见念珠菌菌株抗真菌药物敏感试验
表 4 单变量分析肿瘤患者真菌血症30天死亡率
表 5 多变量分析肿瘤患者真菌血症30天死亡率
-
[1] Morii D, Seki M, Binongo JN, et al. Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan[J]. J Infect Chemother, 2014, 20(9):558-562. doi: 10.1016/j.jiac.2014.05.009 [2] Kullberg BJ, Campion EW, Arendrup MC. Invasive Candidiasis[J]. N Engl J Med, 2015, 373(15):1445-1456. doi: 10.1056/NEJMra1315399 [3] Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections[J]. N Engl J Med, 2014, 370 (13):1198-1208. doi: 10.1056/NEJMoa1306801 [4] Chowdhary A, Cleveland AA, Harrison LH, et al. Declining incidence of candidemia and the shifting epidemiology of candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance[J]. PLoS One, 2015, 10(3):e0120452. doi: 10.1371/journal.pone.0120452 [5] Li D, Xia R, Zhang Q, et al. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study[J]. BMC Infect Dis, 2017, 17(1):6. doi: 10.1186/s12879-016-2128-4 [6] Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem[J]. Clin Microbiol Rev, 2007, 20(1): 133-163. doi: 10.1128/CMR.00029-06 [7] Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients[J]. Clin Infect Dis, 2003, 37(5): 634-643. doi: 10.1086/376906 [8] Ding X, Yan D, Sun W, et al. Epidemiology and risk factors for nosocomial non-candida albicanscandidemia in adult patients at a tertiary care hospital in north China[J]. Med Mycol, 2015, 53(7):684-690. doi: 10.1093/mmy/myv060 [9] Montagna MT, Caggiano G, Lovero G, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)[J]. Infection, 2013, 41(3):645-653. doi: 10.1007/s15010-013-0432-0 [10] Mikulska M, Bassetti M, Ratto S, et al. Invasive candidiasis in non-hematological patients[J]. Mediterr J Hematol Infect Dis, 2011, 3(1): e2011007. doi: 10.4084/mjhid.2011.007 [11] Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality[J]. Antimicrob Agents Chemother, 2005, 49(9):3640-3645. doi: 10.1128/AAC.49.9.3640-3645.2005 [12] Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2 000 bloodstream candida isolates in the United States[J]. Antimicrob Agents Chemother, 2003, 47(10):3149-3154. doi: 10.1128/AAC.47.10.3149-3154.2003 [13] Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program[J]. J Clin Microbiol, 2004, 42(4):1519-1527. doi: 10.1128/JCM.42.4.1519-1527.2004 [14] Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia[J]. J Clin Microbiol, 2007, 45(6): 1843-1850. doi: 10.1128/JCM.00131-07 [15] Melo AS, Bizerra FC, Freymüller E, et al. Biofilm production and evaluation of antifungal susceptibility amongst clinical candidaspp. isolates, including strains of the candida parapsilosiscomplex[J]. Med Mycol, 2011, 49(3):253-262. https://academic.oup.com/mmy/article/49/3/253/1093714 [16] Serefhanoglu K, Timurkaynak F, Can F, et al. Risk factors for candidemia with non-albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis[J]. J Formos Med Assoc, 2012, 111(6):325-332. doi: 10.1016/j.jfma.2011.03.004 [17] Fu J, Ding Y, Wei B, et al. Epidemiology of candida albicans and non-calbicans of neonatal candidemia at a tertiary care hospital in western China[J]. BMC Infect Dis, 2017, 17(1):329. doi: 10.1186/s12879-017-2423-8 [18] Li C, Wang H, Yin M, et al. The differences in the epidemiology and predictors of death between candidemia acquired in intensive care units and other hospital settings[J]. Intern Med, 2015, 54(23):3009- 3016. doi: 10.2169/internalmedicine.54.3744 [19] Jung DS, Farmakiotis D, Jiang Y, et al. Uncommon candida species fungemia among cancer patients, houston, texas, USA[J]. Emerg Infect Dis, 2015, 21(11):1942-1950. http://cn.bing.com/academic/profile?id=365d39d119cc3b15e1d9a2804cd9cd7a&encoded=0&v=paper_preview&mkt=zh-cn [20] Bergamasco MD, Garnica M, Colombo AL, et al. Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil[J]. Mycoses, 2013, 56(3):256-263. doi: 10.1111/myc.12013 [21] Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of candida spp. to caspofungin: four years of global surveillance[J]. J Clin Microbiol, 2006, 44(3):760-763. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_1393154 [22] Pfaller MA, Boyken L, Hollis RJ, et al. Global surveillance of in vitro activity of micafungin against candida: a comparison with caspofungin by CLSI-recommended methods[J]. J Clin Microbiol, 2006, 44(10):3533- 3538. doi: 10.1128/JCM.00872-06 [23] Horasan EŞ, Ersöz G, Göksu M, et al. Increase in Candida parapsilosis fungemia in critical care units: A 6-years study[J]. Mycopathologia, 2010, 170(4):263-268. doi: 10.1007/s11046-010-9322-5 [24] Almirante B, Rodriguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in barcelona, spain, from 2002 to 2003[J]. J Clin Microbiol, 2006, 44(5):1681- 1685. doi: 10.1128/JCM.44.5.1681-1685.2006 [25] Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen[J]. Clin Microbiol Rev, 2008, 21(4):606-625. doi: 10.1128/CMR.00013-08 [26] Bonassoli LA, Bertoli M, Svidzinski TIE. High frequency of candida parapsilosis on the hands of healthy hosts[J]. J Hosp Infect, 2005, 59 (2):159-162. doi: 10.1016/j.jhin.2004.06.033 [27] Clark TA, Slavinski SA, Morgan J, et al. Epidemiologic and molecular characterization of an outbreak of candida parapsilosis bloodstream infections in a community hospital[J]. J Clin Microbiol, 2004, 42(10): 4468-4472. doi: 10.1128/JCM.42.10.4468-4472.2004 [28] Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care[J]. BMC Infect Dis, 2006, 6(1):21. doi: 10.1186/1471-2334-6-21 [29] abino R, Verissimo C, Brandao J, et al. Epidemiology of candidemia in oncology patients: a 6-year survey in a portuguese central hospital[J]. Med Mycol, 2010, 48(2):346-354. https://www.onacademic.com/detail/journal_1000037683344710_3d03.html [30] Gamaletsou MN, Walsh TJ, Zaoutis T, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies[J]. Clin Microbiol Infect, 2014, 20(1):O50- O57. doi: 10.1111/1469-0691.12312
计量
- 文章访问数: 87
- HTML全文浏览量: 5
- PDF下载量: 3
- 被引次数: 0